Expression Analysis of Long Non-coding RNAs CCAT1, CCHE1, ANRIL, BANCR, and PICART1 in Lung Cancer

Subject Areas : Journal of Animal Biology

Nahid Shafaghat ¹ , Soudeh Ghafouri-Fard ² , Fattah Sotoodehnejadnematalahi ³

1 - Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
2 - Department of Medical Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 - Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran

Received: 2021-04-10 Accepted : 2021-06-12 Published : 2021-11-22

Keywords: Lung Cancer, CCAT1, CCHE1, ANRIL, BANCR, PICART1, lncRNAs,

Abstract :

Lung cancer is the most common malignancy with the highest mortality worldwide. LncRNAs play complex roles in the initiation and progression of lung cancer, thereby affecting the prognosis of patients. In this study, the expression changes of CCAT1, CCHE1, ANRIL, BANCR, and PICART1 lncRNAs in tumor tissues compared to normal tissues adjacent to the tumor were investigated and their potential as biomarkers for the diagnosis and prognosis of lung cancer was evaluated. In order to conduct this case-control study, 30 samples of lung cancer tissue and 30 samples of adjacent non-cancerous tissues (ANCTs) were collected and after total RNA extraction and cDNA synthesis, the expression levels of target lncRNAs and β2M reference gene was measured using SYBR Green real-time PCR assay. The statistical analysis of Real-time PCR data showed no significant difference between the expression of these lncRNAs in tumor tissue and normal tissue adjacent to the tumor (P> 0.05). Furthermore, no significant association was observed between the expression level of these lncRNAs and any of the demographic and pathological characteristics of patients (P> 0.05). Based on the findings of this study, it can be concluded that these lncRNAs play no role in lung cancer in Iranian patients. However, to confirm our results, it is necessary to evaluate the expression of these lncRNAs in a larger number of samples..

References:

1. Bray F., Ferlay J., Soerjomataram I., Siegel R. L., Torre L. A., Jemal A. 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6): 394–424.


2. Cech T. R., Steitz J. A. 2014. The noncoding RNA revolution - Trashing old rules to forge new ones. Cell, 157(1): 77-94.


3. Chen J., Zhang K., Song H., Wang R., Chu X., & Chen, L. 2016. Long noncoding RNA CCAT1 acts as an oncogene and promotes chemoresistance in docetaxel-resistant lung adenocarcinoma cells. Oncotarget, 7(38): 62474–62489.


4. Hu B., Zhang H., Wang Z., Zhang F., Wei H., Li L. 2017. LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4. Cancer Biology and Therapy, 18(12): 974–983.


5. Huarte M. 2015. The emerging role of lncRNAs in cancer. Nature Medicine, 21(11): 1253-1261.


6. Inamura K. 2017. Lung cancer: understanding its molecular pathology and the 2015 wHO classification. Frontiers in Oncology, 7: 193.


7. Li N., Hao W., Yang J., Guo Y., Guo Y., Du Y. 2020. Long non-coding RNA colon cancer-associated transcript-1 regulates tumor cell proliferation and invasion of non-small-cell lung cancer through suppressing miR-152. Geriatrics and Gerontology International, 20(6): 629–636.


8. Li Y., Yang Z., Wan X., Zhou J., Zhang Y., Ma H., Bai Y. 2016. Clinical prognostic value of metastasis-associated lung adenocarcinoma transcript 1 in various human cancers: An updated meta-analysis. International Journal of Biological Markers, 31(2): e173–e182.


9. Liao Y., Cheng S., Xiang J., Luo C. 2018. lncRNA CCHE1 increased proliferation, metastasis and invasion of non-small lung cancer cells and predicted poor survival in non-small lung cancer patients. European Review for Medical and Pharmacological Sciences, 22(6): 1686–1692.


10. Lin C., & Yang L. 2018. Long Noncoding RNA in Cancer: Wiring Signaling Circuitry. Trends in Cell Biology, 28(4): 287-301.


11. Lin H., Cheng W., Yan H., Zhang, X. 2018. Overexpression of the long noncoding rna ccat1 promotes metastasis via epithelial-to-mesenchymal transition in lung adenocarcinoma. Oncology Letters, 16(2): 1809–1814.


12. Lin L., Gu Z. T., Chen W. H., Cao, K. J. 2015. Increased expression of the long non-coding RNA ANRIL promotes lung cancer cell metastasis and correlates with poor prognosis. Diagnostic Pathology, 10(1): 14.


13. Lu Y., Zhou X. H., Xu L., Rong C. H., Shen C., Bian W. 2016. Long noncoding RNA ANRIL could be transactivated by c-Myc and promote tumor progression of non-small-cell lung cancer. OncoTargets and Therapy, 9: 3077–3084.


14. Naemura M., Murasaki C., Inoue Y., Okamoto H., Kotake Y. 2015. Long noncoding RNA ANRIL regulates proliferation of non-small cell lung cancer and cervical cancer cells. Anticancer Research, 35(10): 5377–5382.


15. Nakagawa T., Endo H., Yokoyama M., Abe J., Tamai K., Tanaka N., Sato I., Takahashi S., Kondo T., Satoh K. 2013. Large noncoding RNA HOTAIR enhances aggressive biological behavior and is associated with short disease-free survival in human non-small cell lung cancer. Biochemical and Biophysical Research Communications, 436(2): 319–324.


16. Nie F. Q., Sun M., Yang J. S., Xie M., Xu T. P., Xia R., Liu Y. W., Liu X. H., Zhang E. B., Lu K. H., Shu Y. Q. 2015. Long noncoding RNA ANRIL promotes non-small cell lung cancer cell proliferation and inhibits apoptosis by silencing KLF2 and P21 expression. Molecular Cancer Therapeutics, 14(1): 268–277.


17. Sun M., Liu X. H., Wang K. M., Nie F. qi, Kong R., Yang J. song, Xia R., Xu T. P., Jin F. Y., Liu Z. J., Chen J. fei, Zhang E. B., De W., Wang Z. X. 2014. Downregulation of BRAF activated non-coding RNA is associated with poor prognosis for non-small cell lung cancer and promotes metastasis by affecting epithelial-mesenchymal transition. Molecular Cancer, 13(1): 68.


18. Walters S., Maringe C., Coleman M. P., Peake M. D., Butler J., Young N., Bergström S., Hanna L., Jakobsen E., Kölbeck K., Sundstrøm S., Engholm G., Gavin A., Gjerstorff M. L., Hatcher J., Johannesen T. B., Linklater K. M., McGahan C. E., Steward J., Tracey E., Turner D., Richards M.A., Rachet B. 2013. Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: A population-based study, 2004-2007. Thorax, 68(6): 551–564.


19. Wei M. M., Zhou G. B. 2016. Long Non-coding RNAs and Their Roles in Non-small-cell Lung Cancer. Genomics, Proteomics and Bioinformatics, 14(5): 280-288.


20. Wei M. M., Zhou Y. C., Wen Z. S., Zhou B., Huang Y. C., Wang G. Z., Zhao X. C., Pan H. L., Qu L. W., Zhang J., Zhang C., Cheng X., Zhou G. B. 2016. Long non-coding RNA stabilizes the Y-box-binding protein 1 and regulates the epidermal growth factor receptor to promote lung carcinogenesis. Oncotarget, 7(37): 59556–59571.


21. Yang J., Lin J., Liu T., Chen T., Pan S., Huang W., Li S. 2014. Analysis of lncRNA expression profiles in non-small cell lung cancers (NSCLC) and their clinical subtypes. Lung Cancer.85(2): 110-115


22. Yang L., Liu G. 2019. lncRNA BANCR suppresses cell viability and invasion and promotes apoptosis in non-small-cell lung cancer cells in vitro and in vivo. Cancer Management and Research, 11: 3565–3574.


23. Yu X., Zheng H., Chan M. T., Wu W. K. K. 2017. BANCR: a cancer-related long non-coding RNA. American Journal of Cancer Research, 7(9): 1779–1787.


24. Zhang C., Su C., Song Q., Dong F., Yu S., Huo J. 2018. LncRNA PICART1 suppressed non-small cell lung cancer cells proliferation and invasion by taPotential clinical application of lncRNAs in non-small cell lung cancerrgeting AKT1 signaling pathway. American Journal of Translational Research, 10(12): 4193–4201.


25. Zhao J. M., Cheng W., He X. G., Liu Y. L., Wang F. F., Gao,Y. F. 2018. Long non-coding RNA PICART1 suppresses proliferation and promotes apoptosis in lung cancer cells by inhibiting JAK2/STAT3 signaling. Neoplasma, 65(5): 779–789.


26. Zhao L., Wang L., Wang Y., Ma P. 2020. Long non‑coding RNA CCAT1 enhances human non‑small cell lung cancer growth through downregulation of microRNA‑218. Oncology Reports, 43(4): 1045–1052.